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Abstract
Background: We have previously reported that inhibition of astrocytic activation contributes to the analgesic
effects of intrathecal ketamine on spinal nerve ligation (SNL)-induced neuropathic pain. However, the underlying
mechanisms are still unclear. c-Jun N-terminal kinase (JNK), a member of mitogen-activated protein kinase (MAPK)
family, has been reported to be critical for spinal astrocytic activation and neuropathic pain development after SNL.
Ketamine can decrease lipopolysaccharide (LPS)-induced phosphorylated JNK (pJNK) expression and could thus
exert its anti-inflammatory effect. We hypothesized that inhibition of astrocytic JNK activation might be involved in
the suppressive effect of ketamine on SNL-induced spinal astrocytic activation.
Methods: Immunofluorescence histochemical staining was used to detect SNL-induced spinal pJNK expression and
localization. The effects of ketamine on SNL-induced mechanical allodynia were confirmed by behavioral testing.
Immunofluorescence histochemistry and Western blot were used to quantify the SNL-induced spinal pJNK
expression after ketamine administration.
Results: The present study showed that SNL induced ipsilateral pJNK up-regulation in astrocytes but not microglia
or neurons within the spinal dorsal horn. Intrathecal ketamine relieved SNL-induced mechanical allodynia without
interfering with motor performance. Additionally, intrathecal administration of ketamine attenuated SNL-induced
spinal astrocytic JNK activation in a dose-dependent manner, but not JNK protein expression.
Conclusions: The present results suggest that inhibition of JNK activation may be involved in the suppressive
effects of ketamine on SNL-induced spinal astrocyte activation. Therefore, inhibition of spinal JNK activation may be
involved in the analgesic effects of ketamine on SNL-induced neuropathic pain.
Background
Spinal glial activation is both required and sufficient for
neuropathic pain after nerve injury [1-4]. Previous stu-
dies have also shown that spinal astrocytes and micro-
glia are two key players in the induction and
maintenance of neuropathic pain [5-7]. Specifically,
astrocytes play a pivotal role in the maintenance of
spinal nerve ligation (SNL)-induced neuropathic pain
[8-10]. Accumulating evidence shows that mitogen-
activated protein kinases (MAPKs), activated in spinal
glia, play an important role in signaling cascades of
inflammatory mediators during nerve injury-induced
neuropathic pain [10-14]. There are three major MAPK
family members: extracellular signal-regulated kinase
(ERK), p38, and c-Jun N-terminal kinase (JNK) [11].
Ligation of the 5
th lumbar nerve results in activation of
all three MAPKs in spinal cord and dorsal root ganglion
(DRG), but each one has its own expression time
window and different cellular localization [8,10,15]. Acti-
vated p38 is specifically localized within microglia but
not neurons or the astrocytes in the spinal dorsal horn
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any medium, provided the original work is properly cited.early after the lesion, which suggests that p38 activation
in spinal microglia is likely to have a substantial role in
the early phase of neuropathic pain [15,16]. Compared
with p38, the JNK pathway is specific for spinal astro-
cyte activation in SNL-induced neuropathic pain [8,17].
SNL-induced transient activation of JNK in DRG neu-
rons is involved in inducing neuropathic pain, whereas
persistent activation of JNK in spinal astrocytes seems
to be critical for maintaining SNL-induced neuropathic
pain [8]. In particular, inhibition of JNK activation could
alleviate neuropathic pain after SNL [8,17]. Therefore,
inhibition of the JNK pathway during activation of
spinal astrocytes could be the underlying mechanism of
action for analgesics.
Intrathecal ketamine has been reported to have an evi-
dent analgesic effect on neuropathic pain induced by
nerve injury or other causes in animal and clinical stu-
dies [18-20]. A number of studies have been carried out
to elucidate the mechanisms underlying this analgesic
effect, but without satisfying output. Previous study [21]
showed that both intraperitoneal and intrathecal
ketamine inhibit SNL-induced allodynia; however,
intrathecal but not intraperitoneal ketamine suppresses
SNL-induced astrocytic activation as reflected by down-
regulated glial fibrillary acidic protein (GFAP) expres-
sion. These results suggest that intraperitoneal ketamine
could alleviate SNL-induced neuropathic pain via classi-
cal “neuronal-based” mechanisms but, in addition,
“astrocyte-related” mechanisms may also be important
in underlying the anti-allodynic effect of intrathecal
ketamine. Interestingly, ketamine can inhibit lipopoly-
saccharide (LPS)-induced astrocyte activation [22], and
can also decrease LPS-induced JNK phosphorylation
(pJNK) to inhibit pro-inflammatory gene expression in
macrophages [23]. Therefore, we hypothesized that inhi-
biting activation of JNK pathway might be involved in
the suppressive effect of ketamine on SNL-induced
spinal astrocyte activation.
In the present study, the expression and localization
of SNL-induced spinal pJNK was detected by
immunofluorescence. Then, the effects of ketamine on
SNL- induced mechanical allodynia were confirmed by
behavioral testing. Finally, changes in SNL-induced
pJNK expression after ketamine administration were
quantified using immunofluorescence histochemistry
and western blot.
Methods
Animal preparation
Male Sprague-Dawley rats (180-200 g) were housed in
plastic cages, and maintained on a 12:12 h light/dark
cycle under conditions of 22-25°C ambient temperature
with food and water available. All efforts were made to
minimize animal suffering and to reduce the number of
animals used. All experimental procedures received
prior approval from the Animal Use and Care Commit-
tee for Research and Education of the Fourth Military
Medical University (Xi’an, China), and the ethical guide-
lines to investigate experimental pain in conscious
animals [24].
Intrathecal implantation
Intrathecal implantation was performed by inserting a
polyethylene (PE) tube (Becton Dickinson and Company,
USA) directly into the subarachnoid space of the lumbar
enlargement to inject drugs. Briefly, a midline incision
(3 cm) was made at the back of the rat from the level of
the 3
th thoracic vertebrae to the lower back, under pento-
barbital anesthesia (45 mg kg
-1, i.p.). A pre-measured
length of PE-10 tube (I.D. 0.28 mm and O.D. 0.61 mm)
was passed caudally from the T8 to the L3 level of the
spinal cord, and 2 cm of the free ending was left exposed
in the upper thoracic region. Only animals judged to be
neurologically normal and that showed complete paraly-
sis of the tail and bilateral hind legs after administration
of 2% lidocaine (10 μl) through the intrathecal catheter
were used for the following experiments. Rats were
allowed to recover for a 3-5 d period before further use.
Spinal nerve ligation
To create the rat SNL model, under pentobarbital
anesthesia (45 mg kg
-1, i.p.), the left transverse process
of the L6 vertebra was first removed to expose the L4
and L5 spinal nerves. The L5 spinal nerve was then
carefully isolated and tightly ligated with 6-0 silk thread
[25]. The surgical procedure for the sham group was
identical to that of the SNL group, except that the spinal
nerve was not ligated. The animals were followed for
1 w before intrathecal drug administrations were admi-
nistered from post operative day (POD) 8 to POD 10.
Intrathecal drug administrations
S(+)-ketamine hydrochloride (Sigma, St. Louis, MO,
USA) was dissolved and diluted with preservative-free
normal saline solution for administration. Normal saline
(0.9%) was used as the negative control. Animals were
divided into 4 groups for administration: a Sham-Saline
group (n = 10, a volume of 10 μl normal saline was
injected into Sham rats), an SNL-Saline group (n = 10, a
volume of 10 μl normal saline was injected into SNL
rats), an SNL-ketamine group (n = 30; 10 for each of
the 3 subgroups; 10 μl of 30, 100 or 300 μgk g
-1 keta-
mine was injected into SNL rats, respectively); and a
Sham-ketamine group (n = 30; 10 for each of the 3 sub-
groups; 10 μl of 30, 100 or 300 μgk g
-1 ketamine was
injected into Sham rats, respectively). Drugs and normal
saline were injected intrathecally over 30 s, followed by
a1 0μl flush of normal saline. The dosages of ketamine
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previous research [18,21] and pilot experiments.
Nociceptive behavioral testing
Animals were habituated to the testing environment for
3 d before baseline testing, and then were placed under
inverted plastic boxes (30 × 30 × 50 cm
3)o na ne l e v a t e d
mesh floor and allowed to habituate for 30 min before the
threshold testing. Briefly, a logarithmic series of 8 cali-
brated Semmes-Weinstein monofilaments (von-Frey hairs;
Stoelting, Kiel, WI, USA) were applied to the ipsilateral
hindpaws to determine the stimulus intensity threshold
stiffness required to elicit a paw withdrawal response. Log
stiffness of the hairs is determined by log10 (milligrams ×
10) [4]. The 8 filaments had the following log-stiffness
values (value in grams is given in parentheses): 4.17 (1479
mg), 4.31 (2041 mg), 4.56 (3630 mg), 4.74 (5495 mg), 4.93
(8511 mg), 5.07 (11749 mg), 5.18 (15136 mg), and 5.46
(28840 mg). The range of monofilaments (1.479-28.840
gm) produced a logarithmically graded slope when inter-
polating a 50% response threshold of stimulus intensity
(expressed as log10 (milligrams × 10)) [26]. The behavioral
responses were used to calculate the 50% paw-withdrawal
threshold (PWT, absolute threshold), by fitting a Gaussian
integral psychometric function using a maximum-
likelihood fitting method, as described in detail previously
[4]. This fitting method allowed parametric statistical
analysis. Assessments were made before surgery for base-
line value. Then, behavioral tests were performed once a
day until POD 10. Intrathecal drug administrations were
carried out 30 min before behavioral test from POD 8 to
POD 10. All the PWT tests were performed in a double-
blind manner.
Rotarod testing
In order to assess whether the drugs used in the pre-
sent experiment could influence motor function, which
might influence the behavioral results, we performed
rotarod tests on drug-administered but operation- and
behavioral observation-free rats. Rats with no previous
exposure to the rotarod test were placed on the Ugo
Basile 7650 Rotarod accelerator treadmill (Ugo Basile,
Varese, Italy) set at the minimal speed for training ses-
sions of 1-2 min at intervals of 30-60 min. After this
learning period, the animals were placed on to the
rotarod at a constant speed of 25 RPM.A st h ea n i m a l
took a grip on the drum, the accelerator mode was
selected on the treadmill, i.e. the rotation rate of the
drum was increased linearly at 20 RPM. Thereafter,
the time was measured from the start of the accelera-
tion period until the rat fell off the drum. The cut-off
time was 30 s. The test was done 30 min after
intrathecal ketamine or saline once a day for 3 days.
The time that the animal remained on the rotarod was
recorded and expressed as a percentage of its own
baseline value.
Immunofluorescent histochemical staining
After deep anesthesia was induced using pentobarbital
(60 mg kg
-1, i.p.), rats were perfused through the
ascending aorta with 100 ml 0.9% saline followed by
500 ml 0.1 M phosphate buffer (PB, pH 7.3) that
contained 4% paraformaldehyde and 2% picric acid. After
perfusion, the L5 spinal segment was removed and post-
fixed in the same fixative for 2-4 h and then cryoprotected
for 24 h at 4°C in 0.1 M PB that contained 30% sucrose.
Transverse frozen spinal sections (30 μmi nt h i c k n e s s )
were cut with a cryostat (Leica CM1800; Heidelberg,
Germany) and collected serially into three dishes. Each
dish contained a complete set of serial sections.
T h es e c t i o n si nt h ef i r s td i s hw e r er i n s e di n0 . 0 1M
phosphate-buffered saline (PBS, pH 7.3) three times
(10 min each), blocked with 2% goat serum in 0.01 M PBS
that contained 0.3% Triton X-100 for 1 h at room tem-
perature (RT, 20-25°C), and then used for immunofluores-
cent histochemical staining. The sections were incubated
overnight at 4°C with rabbit anti-phosphorylated JNK
(pJNK) antibody (1:1000; Cell Signaling Technology,
Beverly, MA, USA). The sections were washed three times
in 0.01 M PBS (10 min each) and then incubated for 4 h
at RT with the secondary antibody: Alexa 488 donkey
anti-rabbit IgG (1:500; Invitrogen, Carlsbad, CA).
Other primary antibodies used in this study were mono-
clonal antibodies: mouse anti-neuronal-specific nuclear
protein (NeuN) (1:3000; Chemicon, Temecula, CA),
mouse anti-glial fibrillary acidic protein (GFAP) (1:5000;
Chemicon, Temecula, CA), and mouse anti-cd11b clone
ox42 (1:500; Abcam, Cambridge, UK). For double immu-
nofluorescence, sections were incubated with a mixture of
two primary antibodies followed by a mixture of the two
respective secondary antibodies (Alexa 488 donkey anti-
rabbit IgG and Alexa 594 donkey anti-mouse IgG, 1:500;
Invitrogen, Carlsbad, CA). Confocal images were obtained
using a confocal laser microscope (FV1000; Olympus,
Tokyo, Japan) and digital images were captured with Fluo-
view 1000 (Olympus). The excitation peak wavelength was
495 nm for Alexa 488 or 590 nm for Alexa 594, and the
emission peak wavelength was 519 nm for Alexa 488 or
617 nm for Alexa 594.
The specificity of the staining was tested on the
sections in the second dish by omission of the primary
specific antibodies. No immunoreactive products were
found on these sections. Sections in the third dish were
used for Nissl staining (data not shown).
Western blot
Animals were sacrificed after inducing deep anesthesia
(pentobarbital, 60 mg kg
-1, i.p.) and the L5 dorsal horns
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dissected using the “open book” method [10]. Briefly,
the L5 spinal cord segment was dissected according to
the termination of the L4 and L5 dorsal roots. Then, the
spinal segment was cut into a left and right half from
the midline. Finally, the left half was further split into
the dorsal and ventral horns at the level of the central
canal. The selected region was homogenized with a
hand-held pestle in sodium dodecyl sulfate (SDS) sample
buffer (10 ml mg
-1 tissue), which contained a cocktail of
proteinase and phosphatase inhibitors. The electrophor-
esis samples were heated at 100°C for 5 min and loaded
onto 10% SDS-polyacrylamide gels with standard
Laemmli solutions (Bio-Rad Laboratories, CA, USA).
The proteins were electroblotted onto a polyvinylidene
difluoride membrane (PVDF, Immobilon-P, Millipore,
Billerica, MA, USA). The membranes were placed in a
blocking solution, which contained Tris-buffered saline
with 0.02% Tween (TBS-T) and 5% non-fat dry milk, for
1 h, and incubated overnight under gentle agitation with
primary antibody rabbit anti-pJNK (1:1000; Cell Signal-
ing Technology, Beverly, MA), rabbit anti-JNK (1:1000;
Cell Signaling Technology) and mouse anti-b-actin
(1:1000; Sigma, St Louis, MO, USA) respectively. Bound
primary antibodies were detected with a horseradish
peroxidase (HRP)-conjugated anti-rabbit or anti-mouse
secondary antibody (1:10000; Amersham Pharmacia
Biotech Inc., Piscataway, NJ, USA). Between each step,
the immunoblots were rinsed with TBS-T. All reactions
were detected by the enhanced chemiluminescence
(ECL) detection method (Amersham). The densities of
protein blots were analyzed by using Labworks Software
(Ultra-Violet Products, UK). The densities of pJNK, JNK
and b-actin immunoreactive bands were quantified with
background subtraction. Squares of identical sizes were
drawn around each band to measure density, and back-
ground near that band was subtracted. Since b-actin
levels didn’t change significantly after inflammation and
nerve injury [27], we used b-actin levels as loading con-
trols, and pJNK or JNK levels were normalized against
b-actin levels.
Quantification and statistical analysis
All data were collected and analyzed by researchers
blinded to the surgery and reagents used.
Data from immunofluorescence were calculated as
detailed in our previous report [28]. For quantification
of pJNK-immunopositive cell profiles in spinal cord, five
nonadjacent sections (30 μm) from L5 segments were
selected randomly from each animal. In each group,
6 rats were used for statistical analysis. Images (450 × 338
μm
2) of the medial two-thirds of the superficial dorsal
horn (laminas I-III) were captured under a 20 × objective
[8]. All positively stained cells in the area were evaluated
using a computer-assisted image analysis program
(MetaMorph 6.1), which set low and high thresholds for
immunofluorescent intensity determined by the signal.
The same configuration was used to measure cell areas in
all experimental groups. The measured areas were trans-
ferred to Excel automatically for the following statistic
analysis. MetaMorph 6.1 was calibrated to provide stan-
dardization of area measurements. A standardized field
area was sampled arbitrarily from regions within randomly
selected dorsal horn sections [8]. Data from immunofluor-
escence were expressed as fold change against that of the
Sham-Saline (or Sham) group. ANOVA followed by the
least significant difference test was used for statistical
analysis.
Data from western blots are expressed as mean ± SD.
Differences in changes of values over time of each
group were tested using one-way ANOVA, followed by
t h el e a s ts i g n i f i c a n td i f f e r e n c et e s t .D a t af r o mt h ev o n -
Frey test are presented as mean ± SD and were analyzed
as the interpolated 50% threshold (absolute threshold) in
log base 10 of stimulus intensity (monofilament stiffness
in milligrams × 10). Repeated measures ANOVA (with
Bonferroni confidence interval adjustment) was used
and conducted for analysis. Data from the rotarod test
are presented as mean ± SD, and repeated measures
ANOVA (with Bonferroni confidence interval adjust-
ment) was also used. All statistical analyses were per-
formed using SPSS
® version 16.0 software (SPSS Inc.,
Chicago, IL, USA). P < 0.05 was considered statistically
significant.
Results
SNL induces significant ipsilateral up-regulation of
astrocytic pJNK in spinal dorsal horn
SNL induced a marked pJNK up-regulation in ipsilateral
spinal cord (Figure 1A), especially in the superficial dor-
sal horn, while few pJNK-immunopositive cells could be
detected in contralateral spinal dorsal horn 10 days after
SNL (Figure 1B). There was no significant difference in
pJNK expression in spinal dorsal horn between Sham-
Saline (Figure 1C) and naïve (Figure 1D) groups. How-
ever, compared with that of the Sham-Saline group,
SNL induced a much higher expression of pJNK in the
spinal dorsal horn (Figure 1E), indicated by increased
density of immunoreactive staining in high-magnifica-
tion images (Figure 1F).
In order to detect the cellular localization of pJNK
expression, double immunofluorescent staining with anti-
bodies against pJNK and the neuronal marker NeuN, the
microglial specific marker OX42, or the astrocytic speci-
fic marker GFAP was performed, respectively. No coloca-
lization could be observed either between pJNK and
NeuN (Figure 2: A-A’’), or between pJNK and OX42
(Figure 2: B-B’’), which suggests that neither neurons nor
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after SNL. However, all pJNK-positive cells were GFAP-
positive astrocytes (Figure 2: C-C’’).
Effects of ketamine on motor functions indicated by
rotarod testing
Nociceptive behavioral results could be easily influenced
as a result of motor dysfunction. In order to assess
whether the dosages of ketamine used in the present
study (30, 100 and 300 μgk g
-1) could produce impair-
ment of motor functions, 18 otherwise experiment-free
rats were assessed using a rotarod test. Intrathecal
ketamine (30, 100 and 300 μgk g
-1)d i dn o ta f f e c tt h e
motor performance of rats 30 min after injection com-
pared with their own baseline (Figure 3). Furthermore,
repeated administrations did not influence motor func-
tion either.
Ketamine attenuates SNL-induced mechanical allodynia in
a dose-dependent manner
In order to verify the effects of intrathecal ketamine on
SNL-induced neuropathic pain, ketamine was injected
o n c ead a yw i t ht h r e ed i f f e r e nt dosages and changes in
PWT were observed 30 min after injection, from POD 8
to POD 10 (Figure 4).
SNL induced significant mechanical allodynia as
shown in the SNL-Saline group. Compared with that of
the SNL-Saline group, intrathecal injection of 30 μgk g
-1
ketamine did not influence PWT (Figure 4). Intrathecal
ketamine (100 μgk g
-1)e l e v a t e dP W Ts i g n i f i c a n t l ya f t e r
administration (P < 0.05, compared with that of SNL-
Saline). Furthermore, a higher dose of ketamine (300 μg
kg
-1) apparently elevated PWT (P < 0.05, compared with
that of SNL-ketamine 100 μgk g
-1) (Figure 4). However,
neither high (300 μgk g
-1) nor lower doses (30 and 100
μgk g
-1, data not shown) of ketamine changed the basal
threshold in the sham-operated group (Figure 4). These
results demonstrate that intrathecal ketamine (30, 100
and 300 μgk g
-1) produces an effective and reliable
Figure 1 Expression of pJNK in the rat spinal dorsal horn on
postoperative day (POD) 10. A, L5 spinal nerve ligation (SNL)
induced a remarkable c-Jun N-terminal kinase phosphorylation
(pJNK) up-regulation in the ipsilateral lumbar spinal dorsal horn. B,
expression of pJNK in the contralateral lumbar spinal dorsal horn. C
and D, expressions of pJNK in the ipsilateral lumbar spinal dorsal
horn in Sham-Saline and naïve groups. E, up-regulation of pJNK in
the ipsilateral lumbar spinal dorsal horn after SNL. F, a high-
magnification image from the rectangle area of E shows a high
density of pJNK-immunoreactive staining in the ipsilateral lumbar
spinal dorsal horn after SNL. G, statistical analysis of pJNK expression
in different groups. * indicates a statistically significant difference
(P < 0.05) between groups. Six rats in each group. Scale bars: 200
μm in A and B, 100 μm in C, D and E, 20 μmi nF .
Figure 2 Cellular localization of pJNK expression in spinal
dorsal horn after SNL. High-magnification images demonstrated
the results of double immunofluorescent histochemical staining with
NeuN and pJNK (A-A’’), with OX-42 and pJNK (B-B’’), or with glial
fibrillary acidic protein (GFAP) and pJNK (C-C’’). Scale bar: 50 μm.
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SNL-induced neuropathic pain.
Effects of intrathecal ketamine on SNL-induced pJNK
expression
Next, the effect of intrathecal ketamine on JNK
phosphorylation was tested. Intrathecal ketamine (300
μgk g
-1) did not show any effect on pJNK expression in
sham operated rats compared with that of the Sham-
Saline group (Figure 5:A, B), which was also verified by
western blot (Figure 6A). SNL enhanced expression of
pJNK in spinal dorsal horn (Figure 5C), which was
Figure 3 Effects of ketamine on motor performance of rats in
the rotarod test. After recording baseline response, ketamine (30,
100 or 300 μgk g
-1) was administered intrathecally and rotarod test
was performed 30 min later once a day for 3 days, respectively.
Compared with the baseline response, no statistical differences were
obtained from rotarod test after intrathecal ketamine. There were six
rats in each group. KTM: ketamine.
Figure 4 Effects of intrathecal ketamine on SNL-induced
mechanical allodynia. SNL induced significant mechanical
allodynia as shown by von-Frey tests. Intrathecal 300 μgk g
-1
ketamine did not change the normal pain threshold of the sham-
operated group. Intrathecal ketamine (100 and 300 μgk g
-1) showed
an effective and reliable anti-allodynia effect in a dose-dependent
manner on SNL-induced neuropathic pain, whereas, intrathecally
30 μgk g
-1 of ketamine did not influence pain threshold after SNL at
all. Drugs were given intrathecally once a day from POD 8 to POD
10. *P < 0.05, compared with that of SNL-Saline group.
#P < 0.05,
compared with that of SNL-ketamine 100 μgk g
-1 group. There were
ten rats in each group. KTM: ketamine.
Figure 5 Effect of intrathecal ketamine on SNL-induced pJNK
expression. Only a little pJNK expression could be detected in the
Sham-Saline group (A), and intrathecal ketamine (300 μgk g
-1) had
no effect on pJNK expression in sham-operated rats (B). SNL
induced significant pJNK expression (C), which could be suppressed
by intrathecal ketamine in a dose-dependent manner (D-F). G,
statistical analysis of the pJNK expressions after different treatments.
*, # or $ each indicates statistically significant difference with P <
0.05 between groups. Four rats in each group. Scale bar: 100 μm.
KTM: ketamine.
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pared with that of the Sham-Saline group (Figure 6A, p <
0.05). Intrathecal ketamine produced a dose-dependent
effect on suppression of SNL-induced pJNK up-regula-
tion in spinal dorsal horn (Figure 5:D-F, Figure 6A).
Intrathecal 30 μgk g
-1 ketamine did not show any obvious
effect on pJNK expression compared with that of the
SNL-Saline group (Figure 5D, Figure 6A). However, the
expression of pJNK was significantly attenuated to
59.54% of the SNL-Saline group by intrathecal 100 μgk g
-
1 of ketamine (Figure 5E, Figure 6A, P < 0.05). Moreover,
intrathecal 300 μgk g
-1 ketamine significantly down-regu-
lated pJNK expression (Figure 5F), to just 30.46% that of
the SNL-Saline group (Figure 6A, P < 0.05). Furthermore,
intrathecal 300 μgk g
-1 ketamine showed stronger effects
on pJNK expression compared with that of the SNL-keta-
mine 100 μgk g
-1 ketamine group (Figure 6A, P < 0.05).
These results suggest that intrathecal ketamine can effec-
tively inhibit pJNK up-regulation in a dose-dependent
manner. However, neither SNL operation nor intrathecal
ketamine (30, 100 and 300 μgk g
-1) had any obvious
effect on spinal JNK expression (Figure 6B). This result
suggests that intrathecal ketamine only suppresses activa-
tion of the JNK pathway, without changing spinal expres-
sion of total JNK.
Discussion
We have previously shown that intrathecal ketamine
attenuates SNL-induced neuropathic pain and inhibits
astrocytic activation in lumbar spinal dorsal horn [21].
However, the molecular mechanisms of how ketamine
influences astrocytic function are unclear. In the present
study we show that intrathecal ketamine significantly
suppresses nerve injury-induced mechanical allodynia.
More interestingly, the activation of JNK, which is selec-
tively expressed in spinal astrocytes, could be inhibited
by ketamine. Our results suggest that inhibiting activa-
tion of astrocytic JNK may play an important role in the
analgesic effect of ketamine.
JNK is a member of the mitogen-activated protein
kinase (MAPK) family, which has been shown to have a
critical role in intracellular signal transduction. It has
been confirmed that both JNK1 and JNK2 are constitu-
tively expressed in the spinal cord; however, only phos-
phorylated JNK1 (pJNK1, active form) is increased after
SNL [8]. Thus, for the present study, we focused on the
phosphorylated form of JNK (pJNK1) after SNL and drug
administration. Present res u l t ss h o w e dt h a tJ N Kp h o s -
phorylation was highly up-regulated and specifically loca-
lized in spinal astrocytes. These results are in accord with
a previous report that SNL induces a slow (>3 d) and per-
sistent (>21 d) activation of JNK in spinal astrocytes [8].
Previous reports have confirmed that the JNK pathway
is preferentially activated in spinal astrocytes
[8,11,29,30], which is different from the pERK and
p-p38 pathways at the spinal level after nerve injury
[10,15]. It also has been validated that intrathecal
administration of a JNK inhibitor can suppress spinal
Figure 6 Western blot quantification of JNK and pJNK expressions after different treatments. A: Compared with that of Sham-Saline
group, no difference could be detected in pJNK expression after intrathecal ketamine (300 μgk g
-1) to sham-operated rats, whereas SNL
apparently induced pJNK up-regulation. However, intrathecal ketamine down-regulated SNL-induced pJNK expression in a dose-dependent
manner, which was in accord with the immunofluorescent histochemical staining result. B: Spinal JNK protein expression did not show any
obvious difference after different treatments. *, # or $ each indicates statistically significant difference with P < 0.05 between groups. There were
six rats in each group. KTM: ketamine.
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SNL [8,31]. Present study showed that ketamine sup-
pressed pJNK expression in a dose-dependent manner.
Therefore, this may be the underlying molecular
mechanism for ketamine to inhibit astrocytic activation
and to relief mechanical allodynia, especially after nerve
injury.
Ketamine has been reported to exert anti-inflamma-
tory effects on macrophages stimulated with lipopolysac-
charide (LPS) in vitro and in vivo, with involvement of
toll-like receptors (TLRs) and MAPK pathways (JNK
and ERK) [23,32]. Glial cells, the “immunocytes” of the
CNS, somewhat like macrophages, have been confirmed
to be involved in the immune response in neuropathic
pain condition [33]. Furthermore, it has been reported
that ketamine reduces LPS-induced tumor necrosis
factor (TNF)-a, and prostaglandin E2 (PGE2) produc-
tion in astrocyte cultures to inhibit some LPS-induced
astrocytic inflammatory responses [22]. Therefore,
intrathecal ketamine could attenuate SNL-induced
mechanical allodynia by suppression of astrocytic JNK
activation, which has been verified by the present
research. However, how does ketamine function on
astrocytic JNK activation after intrathecal injection?
Ketamine has been recognized as a nonselective
NMDA receptors antagonist. A previous study has
shown that astrocytic activation is markedly suppressed
by treatment with the NR2B- (a subunit of NMDA
receptor) selective antagonist ifenprodil in neuron-glia
co-cultures, but not in purified astrocytes [34]. For this
reason, blocking NMDA receptor on neurons might be
an indirect method to suppress astrocytic activation
with pJNK expression after intrathecal ketamine.
Evidence indicates that proinflammatory cytokines
such as TNF-a, interleukin (IL)-1b,a n dI L - 6a r ep r i -
mary activators of JNK pathway [12,35,36]. Activation of
JNK pathways also can lead to production and release of
multiple proinflammatory mediators [17,37], which form
an excitatory feedback loop among glial cells and neu-
rons resulting in enhanced excitability and plasticity
[7,33,38,39]. Ketamine can exert anti-inflammatory
effects in vitro and in vivo [40-43]. It is reported that
ketamine can inhibit the effects of TNF-a on cellular
signal transmission [43]. Moreover, it is also confirmed
that ketamine can reduce astrocytic TNF-a expression
and release [22], which may break down the positive
feedback loop and alleviate the neuropathic pain. Conse-
quently, suppression of proinflammatory factors expres-
sion after peripheral nerve injury could be an option for
down-regulating pJNK expression by intrathecal
ketamine.
In addition, accumulating studies have indicated that
TLRs, expressed widely on spinal glia, are involved in
the development of neuropathic pain after nerve injury
[44-46]. It has been suggested that glial TLRs could be
new targets for treatment of neuropathic pain [45].
T L R si ns p i n a lc o r dm a yh a v ear o l ei nt h ee a r l ye s t a b -
lishment of neuropathic pain after peripheral nerve
injury [44,46]. A previous report indicated that TLR3
could mediate signals that induce proinflammatory
cytokine and chemokine gene expression in astrocytes,
which could be prevented by SP600125, a pharmacologi-
cal inhibitor of JNK [37]. This report indicates that
activation of JNK is required for TLR3-mediated proin-
flammatory cytokine and chemokine gene expression in
astrocytes. Additionally, ketamine can inhibit proinflam-
matory gene expression, such as TNF-a, IL-1b, IL-6 and
so on, possibly by suppressing TLRs-mediated signal-
transduction [22,32,40,47]. Accordingly, ketamine might
act on TLRs located on astrocytes and thus inhibit
astrocytic JNK activation and, consequently, neuropathic
pain.
Conclusions
Given the important role of the astrocytic JNK pathway
in neuropathic pain, inhibiting JNK activation could be
useful in the treatment of neuropathic pain. The present
study shows that intrathecal ketamine can down-regu-
late astrocytic pJNK expression and attenuate mechani-
cal allodynia in a dose-dependent manner. Although
more detailed mechanisms need to be further investi-
gated and classified, the present work provides a poten-
tial strategy for treating neuropathic pain.
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